Cover Image

Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients

Background: Efficacy and safety of an intensified dosing (ID) regimen of enteric-coated mycophenolate sodium (EC-MPS), which achieves higher mycophenolic acid exposure early posttransplantation, were evaluated in comparison with a standard dosing (SD) regimen. Methods: In total, 128 de novo kidney t...

Full description

Saved in:
Bibliographic Details
Main Authors: Sommerer, Claudia (Author) , Glander, Petra (Author) , Arns, Wolfgang (Author) , Ariatabar, Tofan (Author) , Kramer, Stefan (Author) , Vogel, Eva-Maria (Author) , Shipkova, Maria (Author) , Fischer, Wolfgang (Author) , Liefeldt, Lutz (Author) , Hackenberg, Ruth (Author) , Schmidt, Jan (Author) , Zeier, Martin (Author) , Budde, Klemens (Author)
Format: Article (Journal)
Language:English
Published: April 15, 2011
In: Transplantation
Year: 2011, Volume: 91, Issue: 7, Pages: 779-785
ISSN:1534-6080
DOI:10.1097/TP.0b013e31820d3b9b
Online Access:Verlag, lizenzpflichtig, Volltext: https://dx.doi.org/10.1097/TP.0b013e31820d3b9b
Get full text
Author Notes:Claudia Sommerer, Petra Glander, Wolfgang Arns, Tofan Ariatabar,Stefan Kramer, Eva-Maria Vogel, Maria Shipkova, Wolfgang Fischer, Lutz Liefeldt, Ruth Hackenberg, Jan Schmidt, Martin Zeier, and Klemens Budde
Description
Summary:Background: Efficacy and safety of an intensified dosing (ID) regimen of enteric-coated mycophenolate sodium (EC-MPS), which achieves higher mycophenolic acid exposure early posttransplantation, were evaluated in comparison with a standard dosing (SD) regimen. Methods: In total, 128 de novo kidney transplant recipients treated with basiliximab induction, cyclosporine A, and steroids were randomized (1:1) to receive EC-MPS as SD (1440 mg/day; n=65) or ID (days 0–14: 2880 mg/day; days 15–42: 2160 mg/day; followed by 1440 mg/day; n=63). Efficacy parameters, safety, and tolerability were assessed over a 6-month study period. The primary endpoint was mean time to first occurrence of treatment failure. Results: Mean time to treatment failure was 130 days (95% confidence interval [CI]: 81–n/a) in the ID group versus 114 days (95% CI: 15–155) in the SD group (P=0.36). Similar percentages (ID 30.2%; SD 36.9%) experienced treatment failure. Biopsy-proven acute rejection occurred in 2 (3.2%) ID versus 11 (16.9%) SD patients (P<0.001). Three (2.3%) deaths (2 SD, 1 ID) and five (3.9%) graft losses (3 SD, 2 ID) occurred. Renal function, incidence of infection, and hematologic disorders were comparable in both study cohorts. Gastrointestinal disorders occurred in 51 (81.0%) ID and 49 (75.4%) SD patients with overall similar tolerability as assessed by the Gastrointestinal Symptom Rating Scale. Conclusion: In this exploratory study, the EC-MPS ID regimen reduced the incidence of rejection and showed a comparable safety and tolerability profile to SD. Further examination of this approach in a larger patient cohort is now warranted to confirm these findings.
Item Description:Gesehen am 19.10.2022
Physical Description:Online Resource
ISSN:1534-6080
DOI:10.1097/TP.0b013e31820d3b9b

Similar Items